Oferta Tecnológica

Fatty acids amides for the treatment of alcohol use disorder

  • Therapy

The consumption of alcohol is widespread in our society, so the abuse or alcohol dependence (alcoholism or AUD) constitutes one of the most prevalent disorders in the world. Among the multiple signaling systems affected by alcohol, it has been confirmed that the proteins involved in endocannabinoid signaling are associated with alcohol use disorder and have an important role in the initiation and maintenance of AUD, also being related to anxiety and other affective disorders caused by alcohol.

Currently there are few treatments approved for AUD that are only addressed to a small part of the patients; likewise, none of them act with the novel mechanism described by this research group.

This research group has shown that the use of an oleic acid amide that has as product a dual ligand, is a combinatorial treatment that achieves additive / synergistic pharmacological effects, decreasing alcohol intake.

The two pharmacological profiles related to the endocannabinoid system have already been used in preclinical AUD models separately, although this time they propose two alternatives that in both cases comprise at least one PPARα agonist (it simultaneously activates the peroxisome proliferatoractivated alpha receptor):

• PPARα agonists in combination with at least one CB1 receptor antagonist.

• PPARα agonists in combination with at least one PPARγ agonist.

The combined preparation can be used to produce a nutraceutical composition (medical food) for its use in the prevention, relief and / or treatment of the alcohol use disorder.

 

You can also visit:

https://www.ibima.eu/grupo_investigacion/neuropsicofarmacologia/


Ventajas


  • There is good efficacy in inhibiting the alcohol intake (both free consumption and occasional relapses), as well as the deposit of liver fat (organism protection against the harm caused by alcohol).

  • It is an innovative performance target. This combined action is unique as a pharmacological model allowing dose reduction, toxicity and increased efficacy.

  • There is an absence of toxicity in preclinical models.

Palabras Clave


Clasificación

  • Autoimmune and inflammation
  • Metabolic diseases and Endocrinology

Inventores de IBIMA


Contacto

Isabel Guerrero

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 671 534 901 Corp.: 63 49 01 isabel.guerrero@ibima.eu

María Mengual

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 689 008 050 maria.mengual@ibima.eu

Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:
-->

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263